CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pacgen Life Science Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pacgen Life Science Corp
701 West Georgia Street
Suite 1500
Phone: (604) 436-4388p:604 436-4388 Vancouver, BC  V7Y 1C6  Canada Fax: (604) 436-4388f:604 436-4388
This company was Merged or Acquired on 9/30/2020.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Pacgen Life Science Corporation, formerly Pacgen Biopharmaceuticals Corporation, is a life sciences company focused on the commercialization of life sciences products and services. The Company has a worldwide license to develop and commercialize an antifungal called P113 (also called PAC-113). It has sublicensed its PAC-113 right to General Biologicals Corporation (GBC), which offers non-prescription over-the-counter (OTC) products containing PAC-113 in Taiwan. P113 is a 12 amino-acid antimicrobial peptide derived from a histatin protein found in saliva. Its P113 is used for the treatment of various oral conditions, as well as vaginal, dermatological and ophthalmic conditions. GBC offers products, such as cosmetic skin-care products, oral hygiene products and intimate hygiene products. The oral healthcare product includes Mr.&Mrs.O. It has conducted a Phase IIb dose-ranging clinical trial for PAC-113. Its oral health and woman health products are in the commercialization stage.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20203/31/2020Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director ChristinaYip 3/28/2018 4/10/2006
Executive Vice President, Business Development, and Interim Chief Financial Officer AndreaChan 3/28/2018 3/28/2018
Lead Independent Director TelvinJu 10/1/2004 10/1/2004
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Pacgen Inc
PBS
Plover Lifesciences Corporation
Xphase Pharmaceuticals Inc.

General Information
Number of Employees: 10 (As of 3/31/2006)
Outstanding Shares: 64,815,969 (As of 6/30/2020)
Stock Exchange: CVE
Fax Number: (604) 436-4388


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 31, 2023